{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:31:11Z","timestamp":1770291071651,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"JW Pharmaceutical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s13300-022-01339-4","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T10:18:39Z","timestamp":1669198719000},"page":"109-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3902-622X","authenticated-orcid":false,"given":"Sang-Yong","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6417-8412","authenticated-orcid":false,"given":"Sungrae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2017.00006","volume":"8","author":"A Chaudhury","year":"2017","unstructured":"Chaudhury A, Duvoor C, Dendi VSR, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8:6.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1339_CR2","volume-title":"Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext","author":"KR Feingold","year":"2000","unstructured":"Feingold KR. Oral and injectable (non-insulin) pharmacological agents for the treatment of type 2 diabetes. Endotext. South Dartmouth: MDTextcom Inc; 2000."},{"issue":"12","key":"1339_CR3","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"4","key":"1339_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4093\/dmj.2021.0156","volume":"45","author":"KY Hur","year":"2021","unstructured":"Hur KY, Moon MK, Park JS, et al. 2021 clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021;45(4):461\u201381.","journal-title":"Diabetes Metab J"},{"issue":"11","key":"1339_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.clinthera.2011.09.028","volume":"33","author":"KR Richard","year":"2011","unstructured":"Richard KR, Shelburne JS, Kirk JK. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther. 2011;33(11):1609\u201329.","journal-title":"Clin Ther"},{"key":"1339_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3389\/fendo.2019.00376","volume":"10","author":"B Ahr\u00e9n","year":"2019","unstructured":"Ahr\u00e9n B. DPP-4 inhibition and the path to clinical proof. Front Endocrinol (Lausanne). 2019;10:376.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1339_CR7","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.2337\/dc06-0703","volume":"29","author":"P Aschner","year":"2006","unstructured":"Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29:2632\u20137.","journal-title":"Diabetes Care"},{"key":"1339_CR8","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/VHRM.S3374","volume":"4","author":"N Mikhail","year":"2008","unstructured":"Mikhail N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vasc Health Risk Manag. 2008;4:1221\u20137.","journal-title":"Vasc Health Risk Manag"},{"key":"1339_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/dom.12174","volume":"16","author":"D Wu","year":"2014","unstructured":"Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab. 2014;16:30\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"1339_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007638","volume":"96","author":"F Wang","year":"2017","unstructured":"Wang F, He Y, Zhang R, Zeng Q, Zhao X. Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Medicine (Baltimore). 2017;96: e7638.","journal-title":"Medicine (Baltimore)"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.2147\/DMSO.S220180","volume":"12","author":"YH Lin","year":"2019","unstructured":"Lin YH, Huang H. Predictors of the efficacy of dipeptidyl peptidase-4 inhibitors in taiwanese patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2019;12:2725\u201333.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"1339_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/1753-0407.12196","volume":"7","author":"X Cai","year":"2015","unstructured":"Cai X, Han X, Luo Y, Ji L. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on \u03b2-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes. 2015;7(3):347\u201359.","journal-title":"J Diabetes"},{"key":"1339_CR13","first-page":"163","volume":"8","author":"S Nishio","year":"2015","unstructured":"Nishio S, Abe M, Ito H. Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability. Diabetes Metab Syndr Obes. 2015;8:163\u201371.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"1339_CR14","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3109\/00498254.2012.731618","volume":"43","author":"S Furuta","year":"2013","unstructured":"Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica. 2013;43(5):432\u201342.","journal-title":"Xenobiotica"},{"issue":"9","key":"1339_CR15","first-page":"745","volume":"40","author":"K Kaku","year":"2012","unstructured":"Kaku K. Efficacy and safety of anagliptin add-on therapy in Japanese patients with type 2 diabetes. Jpn Pharmacol Ther. 2012;40(9):745\u201370.","journal-title":"Jpn Pharmacol Ther"},{"key":"1339_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0965-3","author":"A Chihara","year":"2019","unstructured":"Chihara A, Tanaka A, Morimoto T, et al. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. Cardiovasc Diabetol. 2019. https:\/\/doi.org\/10.1186\/s12933-019-0965-3.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1339_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/dom.13891","volume":"22","author":"J Ghouse","year":"2020","unstructured":"Ghouse J, Isaksen JL, Skov MW, et al. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(2):231\u201342.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1339_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220667","volume":"14","author":"YK Cho","year":"2019","unstructured":"Cho YK, Lee J, Kang YM, et al. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. PLoS ONE. 2019;14(8): e0220667.","journal-title":"PLoS ONE"},{"issue":"1","key":"1339_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12902-021-00791-w","volume":"21","author":"M Urina-Jassir","year":"2021","unstructured":"Urina-Jassir M, Herrera-Parra LJ, Vargas JAH, et al. The effect of comorbidities on glycemic control among Colombian adults with diabetes mellitus: a longitudinal approach with real-world data. Endocr Disord. 2021;21(1):128.","journal-title":"Endocr Disord"},{"issue":"3","key":"1339_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4093\/dmj.2014.38.3.197","volume":"38","author":"JY Jeon","year":"2014","unstructured":"Jeon JY, Kim DJ, Ko SH, et al. Current status of glycemic control of patients with diabetes in Korea: the Fifth Korea National Health and Nutrition Examination Survey. Diabetes Metab J. 2014;38(3):197\u2013203.","journal-title":"Diabetes Metab J"},{"issue":"3","key":"1339_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.4093\/dmj.2011.35.3.282","volume":"35","author":"BY Kim","year":"2011","unstructured":"Kim BY, Jung CH, Mok JO, Kim CH. Factors associated with long-term oral hypoglycemic agent responsiveness in korean patients with type 2 diabetes mellitus. Diabetes Metab J. 2011;35(3):282\u20139.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1339_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00592-020-01590-w","volume":"58","author":"O Ogundipe","year":"2021","unstructured":"Ogundipe O, Mazidi M, Chin KL, et al. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetol. 2021;58(1):39\u201346.","journal-title":"Acta Diabetol"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s13300-019-0628-0","volume":"10","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, Kim YS, Lee CB, et al. Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: a 12-week interim report. Diabetes Ther. 2019;10:1271\u201382.","journal-title":"Diabetes Ther"},{"key":"1339_CR24","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s13300-021-01148-1","volume":"12","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Kim YS, Lee CB, et al. Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week results from a prospective observational study. Diabetes Ther. 2021;12:2907\u201320.","journal-title":"Diabetes Ther"},{"key":"1339_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4172\/2155-6156.1000701","volume":"7","author":"M Tanaka","year":"2016","unstructured":"Tanaka M, Nishimura T, Sekioka R, Itoh H. Dipeptidyl peptidase-4 inhibitor switching as an alternative add-on therapy to current strategies recommended by guidelines: analysis of a retrospective cohort of type 2 diabetic patients. J Diabetes Metab. 2016;7:9.","journal-title":"J Diabetes Metab"},{"key":"1339_CR26","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.2147\/DMSO.S267994","volume":"13","author":"E Han","year":"2020","unstructured":"Han E, Lee M, Lee YH, et al. Effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2020;13:4113\u201321.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"9","key":"1339_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5414\/CP203409","volume":"57","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Tanaka A, Tanaka M, et al. Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther. 2019;57(9):474\u20137.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"1339_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.14740\/jocmr3012w","volume":"9","author":"E Shigematsu","year":"2017","unstructured":"Shigematsu E, Yamakawa T, Oba MS, et al. A randomized controlled trial of vildagliptin versus alogliptin: effective switch from sitagliptin in patients with type 2 diabetes. J Clin Med Res. 2017;9(7):567\u201372.","journal-title":"J Clin Med Res"},{"issue":"2","key":"1339_CR29","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","volume":"434","author":"M Nabeno","year":"2013","unstructured":"Nabeno M, Akahoshi F, Kishida H, et al. A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun. 2013;434(2):191\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1339_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4093\/dmj.2016.40.5.339","volume":"40","author":"K Sung-Ho","year":"2016","unstructured":"Sung-Ho K, Jung-Hwa Y, Woo JL, et al. Gemigliptin: an update of its clinical use in the management of type 2 diabetes mellitus. Diabetes Metab J. 2016;40(5):339\u201353.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1339_CR31","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2337\/dc14-S081","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(1):S81\u201390.","journal-title":"Diabetes Care"},{"key":"1339_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.4137\/BMI.S38440","volume":"11","author":"IS Sherwani","year":"2016","unstructured":"Sherwani IS, et al. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights. 2016;11:95\u2013104.","journal-title":"Biomarker Insights"},{"issue":"2","key":"1339_CR33","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/dom.13891","volume":"22","author":"J Ghouse","year":"2020","unstructured":"Ghouse J, Isaksen J, Shov MW, et al. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(2):231\u201342.","journal-title":"Diabetes Obes Metab"},{"key":"1339_CR34","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2337\/dc20-2439","volume":"44","author":"M Lind","year":"2021","unstructured":"Lind M, Imberg H, Coleman RL, Nerman O, Homlan RR. Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44:2231\u20137.","journal-title":"Diabetes Care"},{"issue":"6","key":"1339_CR35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3109\/14756366.2014.1002402","volume":"30","author":"YS Watanabe","year":"2015","unstructured":"Watanabe YS, Yasuda Y, Kojima Y, et al. Anagliptin, a potent dipeptidyl peptidase IV inhibitor: its single-crystal structure and enzyme interactions. J Enzyme Inhib Med Chem. 2015;30(6):981\u20138.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"1339_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3389\/fendo.2019.00389","volume":"10","author":"B Gallwitz","year":"2019","unstructured":"Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol (Lausanne). 2019;10:389.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"15","key":"1339_CR37","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.3390\/ijerph16152720","volume":"16","author":"K Makrilakis","year":"2019","unstructured":"Makrilakis K. The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect. Int J Environ Res Public Health. 2019;16(15):2720.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1339_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/0091270008325152","volume":"49","author":"P Hu","year":"2009","unstructured":"Hu P, Yin Q, Deckert F, et al. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009;49(1):39\u201349.","journal-title":"J Clin Pharmacol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-022-01339-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01339-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T04:29:51Z","timestamp":1674793791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-022-01339-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s13300-022-01339-4","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"assertion":[{"value":"4 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}